Diagnosis and risk stratification

Comprehensive echocardiographic assessment is utilized to evaluate cardiac parameters before and after procedures such as allogeneic hematopoietic stem cell transplantation . In a cohort of 96 patients, significant changes were observed in diastolic parameters, left ventricular mass, global longitudinal strain, and right ventricular ejection fraction following transplantation .

The impact of dimethyl sulfoxide on cardiac function during allogeneic hematopoietic stem cell transplantation remains unclear .

Cardio-oncology

Cardiovascular effects of cancer therapy

Also called onco-cardiology, cancer cardiotoxicity, chemotherapy heart

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

Cardiotoxicity involves damage to the heart or its function secondary to exposure to toxic substances such as drugs used in chemotherapy, immunotherapy, or radiation.1

Comprehensive echocardiographic assessment is utilized to evaluate cardiac parameters before and after procedures such as allogeneic hematopoietic stem cell transplantation.1 In a cohort of 96 patients, significant changes were observed in diastolic parameters, left ventricular mass, global longitudinal strain, and right ventricular ejection fraction following transplantation.1

New research on Cardio-oncology

The role of ASF1B in disease pathogenesis and treatment: from histone chaperone to clinical target

Cancer Biology & Therapy — Deng Y — Nov 2026

Read paper

dsRNA: mechanisms of gene expression regulation, disease pathogenesis, and therapeutic potential

RNA Biology — 刘水平 — Nov 2026

Read paper

Widening the BRCAness therapeutic window for its synthetic lethality effects with PARP inhibitors

Communications Biology — Fernandez A — Nov 2026

Read paper

Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study

Cancer Medicine — Shi X — Nov 2026

Read paper

Mechanisms of Tumor Cell Invasion: Insights From the Perspective of Epithelial‐to‐Mesenchymal Transition

Cell Biochemistry and Function — Guarino M — Nov 2026

Read paper

Multi-omics survival prediction under modality incompleteness via dynamic modality graphs and product-of-experts fusion

Briefings in Bioinformatics — Xie W — Nov 2026

Read paper

Frequency and Risk Factors of Cancer Therapy-Related Cardiac Dysfunction in Patients Receiving Chemotherapy: A Prospective Cohort Study at a Tertiary Centre.

La Clinica Terapeutica — Chieu L — Nov 2026

Read paper

PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026

Journal of Hematology & Oncology — Wang Z — Oct 2026

Read paper

Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients

Journal of Viral Hepatitis — Pascucci J — Oct 2026

Read paper

Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?

The Medical Journal of Australia — Symonds E — Oct 2026

Read paper

The Zα domain of ADAR1: emerging roles in cancer biology and evidence as a promising therapeutic target

Cancer Biology & Therapy — Teo J — Oct 2026

Read paper

An Optimized Cancer Cachexia Research Model

Current Protocols — Wan Y — Oct 2026

Read paper

All 2,157 Cardio-oncology papers →

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.

Cardio-oncology

Overview

Definition

Diagnosis and risk stratification

Open questions

New research on Cardio-oncology

Key papers

How this page is built

Leading authors